Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Phathom Pharmaceuticals (PHAT) Cash from Financing Activities: 2018-2024

Historic Cash from Financing Activities for Phathom Pharmaceuticals (PHAT) over the last 7 years, with Dec 2024 value amounting to $182.8 million.

  • Phathom Pharmaceuticals' Cash from Financing Activities fell 100.22% to -$271,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $147.9 million, marking a year-over-year decrease of 59.89%. This contributed to the annual value of $182.8 million for FY2024, which is 50.28% down from last year.
  • Latest data reveals that Phathom Pharmaceuticals reported Cash from Financing Activities of $182.8 million as of FY2024, which was down 50.28% from $367.6 million recorded in FY2023.
  • Phathom Pharmaceuticals' 5-year Cash from Financing Activities high stood at $367.6 million for FY2023, and its period low was $44.7 million during FY2021.
  • Over the past 3 years, Phathom Pharmaceuticals' median Cash from Financing Activities value was $182.8 million (recorded in 2024), while the average stood at $223.5 million.
  • As far as peak fluctuations go, Phathom Pharmaceuticals' Cash from Financing Activities crashed by 62.43% in 2020, and later skyrocketed by 206.21% in 2023.
  • Yearly analysis of 5 years shows Phathom Pharmaceuticals' Cash from Financing Activities stood at $114.5 million in 2020, then crashed by 60.94% to $44.7 million in 2021, then skyrocketed by 168.50% to $120.0 million in 2022, then soared by 206.21% to $367.6 million in 2023, then slumped by 50.28% to $182.8 million in 2024.